Authors: Martha Powell, Future Science Group
Merck & Co (NJ, USA) announced today that a Phase III trial assessing the company’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met the pre-specified primary endpoints in patients with hospital-acquired or ventilator-associated bacterial pneumonia, demonstrating non-inferiority to meropenem.
The prospective, randomized, double-blind, non-inferiority study assessed the safety and efficacy of ZERBAXA compared with meropenem in 726 adult patients diagnosed with either hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). The researchers compared ZERBAXA, at an investigational 3g dose, with meropenem 1g, both given intravenously every 8 hours for 8–14 days.
Restricted Content / Members Only
